Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Draft Guidances For 2013 Will Grapple With Biosimilars, Track and Trace, Compounding

Executive Summary

FDA’s Center for Drug Evaluation and Research plans to publish more than 50 new and revised draft guidances this calendar year.

You may also be interested in...



FDA Plans Five Biosimilar, Three Social Media Draft Guidances In 2014

Additional draft guidances address implementation of the Drug Supply Chain Security Act, multiple endpoints in clinical trials, and public disclosure of FDA-sponsored studies.

FDA Antimicrobial Development Draft Guidances Withdrawn Under Rejuvenation Initiative

FDA says the 13 guidances are out of date and of no use to industry; a number of others covering various topics also will be revised or finalized.

Clinical Trial Dropouts, Missing Data Get FDA Attention At GSK Anoro Ellipta Review

More than a year after hints of forthcoming guidance on missing data, agency looks toward future where sponsors do more to retain patients and follow up on those that leave clinical trials.

Related Content

Topics

UsernamePublicRestriction

Register

PS055111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel